Clinical Research Programs

 
News Articles for Clinical Research Programs top ^
2015/1/12
-- New trial of niraparib for the treatment of ovarian cancer to begin in Q1 2015 -- HRD assay to be incorporated into Phase 3 NOVA trial of niraparib in ovarian cancer -- Initial Phase 3 data from NOVA is expected to become available in 2015 --
Sign-up for CORRECTING and REPLACING -- TESARO Announces Expansion of Niraparib Clinical Program and Outlines Late-Stage Program Milestones for 2015 investment picks
2015/1/12
-- New trial of niraparib for the treatment of ovarian cancer to begin in Q1 2015 -- HRD assay to be incorporated into Phase 3 NOVA trial of niraparib in ovarian cancer -- Initial Phase 3 data from NOVA is expected to become available in 2015 --
Sign-up for TESARO Announces Expansion of Niraparib Clinical Program and Outlines Late-Stage Program Milestones for 2015 investment picks
2015/1/12
Specifies Milestones for Botulinum Toxin Product Candidates, Topical RT001 and Injectable RT002, for Aesthetic and Therapeutic Indications NEWARK, Calif., Jan.
Sign-up for Revance Therapeutics Defines Clinical Program Milestones and Provides Financial Guidance for 2015 investment picks
2015/2/24
LAKE FOREST, Calif.
Sign-up for Cryoport Provides Logistics Solution and Services for Kite Pharma's Lead Clinical Program in Cancer Immunotherapy investment picks
2015/2/12
Incyte Corporation (Nasdaq: INCY) today reported 2014 fourth-quarter and year-end financial results, including revenue from Jakafi ® (ruxolitinib). The Company provided 2015 financial guidance while outlining its progress in recruiting multiple pivotal and proof-of-concept trials, including those investigating its portfolio of JAK inhibitors in a variety of cancer types, its IDO1 inhibitor in combination with other immuno-oncology agents and a series of studies investigating several other innovative targeted therapies in mono- and combination-therapy settings.
Sign-up for Incyte Reports 2014 Fourth-Quarter and Year-End Financial Results; Provides 2015 Financial Guidance; Updates Shareholders on Key Clinical Programs investment picks
2015/2/2
SOLANA BEACH, Calif., Feb.
Sign-up for Evoke Pharma Outlines Progress on Clinical Program investment picks
2015/2/4
MORRIS PLAINS, N.J., Feb.
Sign-up for Immunomedics Announces Second Quarter Fiscal 2015 Results and Clinical Program Developments investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Clinical Research Programs
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Clinical Research Activities  |  Next: Clinical Research Study